Paper Details
- Home
- Paper Details
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Author: DokiYuichiro, HaraguchiNaotsugu, HataTaishi, HayashiTaro, KudoToshihiro, MizushimaTsunekazu, MoriMasaki, NishimuraJunichi, SakaiDaisuke, SatohTaroh, SuedaToshinori, SugiuraTakashi, TakahashiHidekazu
Original Abstract of the Article :
Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies. In randomized trials, regorafenib and TAS-102 prolonged survival in patients with mCRC. However, the appropriate selection of regorafenib or...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/27466548
データ提供：米国国立医学図書館（NLM）
Regorafenib and TAS-102: Navigating the Shifting Sands of Metastatic Colorectal Cancer Treatment
The treatment of metastatic colorectal cancer (mCRC) has been revolutionized by the introduction of novel antitumor agents. This study explores the efficacy and safety of two such agents, regorafenib and TAS-102, in patients with mCRC who have progressed after standard therapies.
The study highlights the challenge of choosing between regorafenib and TAS-102 for patients with mCRC, as both drugs have shown promising results in extending survival. While clinical trials have demonstrated their effectiveness, the optimal selection of either drug for a particular patient remains an open question. This underscores the complexity of treating mCRC and the need for personalized approaches.
The Evolving Landscape of Metastatic Colorectal Cancer Treatment
The study reflects the ongoing evolution of mCRC treatment. While both regorafenib and TAS-102 offer hope, the ideal treatment approach for individual patients requires careful consideration, taking into account factors such as disease characteristics and patient preferences.
Embracing the Complexity of Colorectal Cancer Treatment
This study provides valuable insights into the evolving landscape of mCRC treatment. It underscores the need for individualized approaches to ensure that patients receive the most effective therapies. As we continue to explore the desert of mCRC treatment, understanding the unique characteristics of each patient is crucial for finding the best path towards recovery.
Dr.Camel's Conclusion
The treatment of metastatic colorectal cancer is a complex journey through the desert of medicine. This study reveals that while regorafenib and TAS-102 are valuable weapons in our arsenal, the choice of the right path requires careful consideration. It's like finding the most suitable camel for a particular journey through the desert - each patient's needs are unique.
Date :
- Date Completed 2017-01-25
- Date Revised 2022-03-21
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.